Search Results
Prevention of HIV/AIDS (X3)
22-Mar-2009 -
27-Mar-2009
Keystone
Colorado
USA
|
"Most recent research efforts on the prevention of HIV and AIDS has focused on T cell-based vaccines but it is admitted this approach will not prevent HIV and needs to be strengthened by novel approaches to generate HIV neutralizing antibodies. The recent successes or failures of alternative methods of HIV prevention (e.g., microbicides, circumcision), or of AIDS prevention (therapeutic vaccines) should help better understand how HIV vaccines can be used, and require sharing basic understanding and results with the prophylactic vaccine field. However the recent negative results of a major HIV vaccine trial have substantially disorganized the field and limit preparation of a definitive program a year and a half in advance. The goals of the meeting are therefore to focus on the most recent key advances in the understanding of (1) how HIV can be controlled at entry and after infection in 3 joint sessions with the concurrent “HIV Immunobiology” meeting, (2) how T cell-based or antibody-based HIV vaccines can be improved, and (3) what are the results of the current vaccine trials and those of alternative methods of HIV or AIDS prevention and how can they help at re-orientating vaccine researches. Two workshops will provide key information on the definition of immune correlates of protection and their analysis in clinical trials."
|
Registration Deadline: 24-Nov-2008
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?Meetin
|
|
HIV Immunobiology: From Infection to Immune Control (X4)
22-Mar-2009 -
27-Mar-2009
Keystone
Colorado
USA
|
"This meeting will highlight the latest breakthroughs in basic HIV research, ranging from the molecular bases of HIV replication to the host genetic determinants influencing viral spread and disease susceptibility; and from the intricacy of the interaction between HIV and the immune system to the most promising progress in therapeutic development. The meeting will identify new levels of possible intervention to control the progression of HIV-induced disease and, more generally, deepen our understanding of the intimate interaction between retroelements and human hosts. Dynamism will be ensured by having concise, up-to-date talks rather than lengthy lectures, by giving ample room to speakers chosen from the abstracts, and by a close coordination with the concurrent meeting on ""Prevention of HIV/AIDS"". Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting, which will share a keynote address and three plenary sessions with this meeting."
|
Registration Deadline: 24-Nov-2008
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?Meetin
|
|
Chemotactic Cytokines
30-May-2010 -
04-Jun-2010
Lucca (Barga)
Italy
Italy
|
It is 20 years since the definition of chemokines as a functionally and biochemically distinct family of proteins. In this time the family has expanded from a small number of members to the current situation where almost 50 chemokines have been identified. In the intervening years much progress has been made in characterising the structure of chemokines, identifying their receptors and the unravelling the complex biologies in which they participate. As a result of these studies it is now clear that chemokines and their receptors are pivotal players in the orchestration of ‘immune’ tissue organogenesis as well as of the innate and adaptive immune responses. Thus chemokine biology now underpins a broad range of biological specialities. Importantly, ‘translational’ studies have provided incontrovertible evidence of the importance of chemokines and their receptors in a range of prominent pathologies. Thus essentially all immune and inflammatory pathologies have, at their heart, a dysfunction of some sort in either chemokine or chemokine receptor expression or responses. In addition, 2 chemokine receptors (CCR5 and CXCR4) have been shown to play profound roles in HIV pathogenesis through their ability to act as co-receptors for viral entry. Finally, details of the roles for chemokines and their receptors in cancer and cancer metastasis have provided important insights into the orchestration of the complex processes of tumorigenesis. Importantly, these pathology-focused studies have highlighted chemokines and their receptors as prominent therapeutic targets and over 10 years of work in this area is now being reflected in a number of chemokine receptor blockers being approved for clinical use. This Gordon Conference will therefore be a celebration of 20 years of research and innovation in the chemokine field. We will explore the complex and diverse biologies of chemokines and their receptors and will integrate this with an up-to-date understanding of the regulation of these molecules. In addition we will examine recent therapeutic developments and will provide updates on the clinical progress of chemokine-based therapeutics. We hope that this will be a forward looking conference with opportunities for in depth analysis of where our field will be heading in the future. Importantly, whilst the science is key to the success of the conference, we will be holding the meeting in Il Ciocco, Italy. This is a beautiful site and the promise of quality red wine and Italian hospitality can only help to make this a successful meeting. We look forward to seeing you in Il Ciocco in May 2010. Gerry Graham and Antal Rot
|
Registration Deadline: 09-May-2010
http://www.grc.org/programs.aspx?year=2010&program=chemotac
|
|
HIV Biology and Pathogenesis
12-Jan-2010 -
17-Jan-2010
Santa Fe
New Mexico
USA
|
The Keystone Symposia Meeting on HIV Biology and Pathogenesis emphasizes key aspects of the basic virological, cell and molecular biological, and disease aspects of HIV. The focus will be to highlight recent advances in our understanding of HIV/AIDS ranging from the earliest events of transmission, to treatments for infected individuals, to interventions to prevent viral transmission. The goal of the meeting is to emphasize the basic mechanisms of viral replication and the interplay of the virus with the immune system leading to the development of AIDS.
|
Registration Deadline: 12-Jan-2010
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1053&subTab=summary
|
|
Viral Immunity
21-Mar-2010 -
26-Mar-2010
Banff
Alberta
Canada
|
The most exciting recent advances in viral immunity include the increased understanding of the role of innate immune mechanisms, interaction between innate and adaptive immunity, pathogen manipulation of host responses, and activation of immune responses and generation of immune memory. Despite these advances, basic mechanisms of anti-viral immunity are poorly characterized particularly for chronic infections. Efforts are also required to exploit recent research advances to improve vaccine design and therapeutic intervention. This meeting will include both innate and adaptive immunity and juxtapose animal models with human studies as it attempts to foster collaborative efforts between attending viral immunologists and the HIV vaccine researchers in the joint meeting. Expert talks in plenary sessions will encompass the latest in critical areas of viral immunity. Workshops and additional presentations will cover provocative and cutting-edge results from attendees. The meeting objective is to accelerate progress in understanding and manipulating anti-viral immunity to improve human health.
|
Registration Deadline: 21-Mar-2010
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1050&subTab=summary
|
|
Overcoming the Crisis of TB and AIDS
20-Oct-2009 -
25-Oct-2009
Arusha
Tanzania
Tanzania
|
Tuberculosis (TB) is the largest cause of death in the AIDS setting, having caused approximately 50% of all AIDS deaths globally. Each infection on its own manipulates the host immune response to enhance the other infectionï¾’s pathogenicity, and the treatment of each involves long or lifelong therapy of complicated drug regimens. The focus of this Keystone Symposia meeting is to gain deeper insights into the immune pathology and deadly synergism between HIV and TB and its global toll in order to identify new ways to solve this global catastrophe by way of basic scientific discovery, and the development and delivery of vaccines, drugs and care. Mycobacterium tuberculosis survives in the vast majority of infected individuals without causing disease. However, as HIV compromises the immune system it fuels clinical emergence of TB and, as a result, has become the driving force for the current TB epidemics in Subsaharan Africa and Asia. TB in turn drives HIV-1 replication and causes HIV-1 disease progression. In order to effectively tackle this twin epidemic, integrated approaches encompassing basic immunological research, drug discovery, drug and vaccine design and delivery and novel approaches to delivering care in remote and impoverished areas must be integrated. This includes the following: virologic and bacteriologic research on the pathogens themselves; immunologic, molecular and cellular research on the host response; design, development and delivery of drugs and vaccines; development of different technologies for biomarkers of disease and cure; and novel drug and vaccine delivery systems. Moreover, basic discovery must be synergized with novel approaches to the delivery of TB and AIDS care in endemic areas. The overarching goal of the symposium is to gain a broad perspective on the problem of TB/AIDS ï¾– from its impact on life on earth to the basic biology of the organisms, the immune response ï¾– and to develop new paradigms of thinking and responses to deal with the humanitarian catastrophe of TB and AIDS co-infection.
|
Registration Deadline: 20-Oct-2009
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1022&subTab=summary
|
|
HIV Vaccines
21-Mar-2010 -
26-Mar-2010
Banff
Alberta
Canada
|
Traditionally, the Keystone Joint HIV Symposia have integrated vaccines and pathogenesis to comprehensively cover the fieldï¾—from HIVï¾’s fundamental biology to its interaction with the human immune system and how to design a vaccineï¾—and these Joint Symposia have been convened every year. In addition to this Keystone Joint Symposium, there are a couple of other well-established HIV vaccine meetings in the year (CROI and the AIDS Vaccine Conference) that follow a similar format and also often feature a similar line-up of speakers. Since an HIV vaccine is proving to be a particularly recalcitrant problem, a novel approach that facilitates a wider cross-fertilization of ideas would be very valuable and would be welcomed by the broader HIV vaccine research community. To that end, the major development proposed for the 2010 Keystone HIV Vaccine Symposium is to foster innovative ideas and new collaborations with immunology and vaccinology as it pertains to other viral diseases. Specifically, we propose that a new Joint Symposium of HIV Vaccines in conjunction with Viral Immunity be convened. This Joint Symposium would retain the valuable format that includes joint and separate sessions covering general and specific principles.
|
Registration Deadline: 21-Mar-2010
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1051&subTab=summary
|
|
HIV Evolution, Genomics and Pathogenesis (X7)
20-Mar-2011 -
25-Mar-2011
Whistler
British Columbia
Canada
|
Elucidating the molecular mechanisms of HIV pathogenesis relies on understanding the complex interplay between the virus and its host. Increasingly, the field is relying on the power of comparative studies of similar viruses in other species, and on whole genome analyses to elucidate which pathways are critical. The use of evolutionary analyses of both host and virus is also providing novel insights into viral transmission and innate immune responses. This Keystone Symposia meeting will use diverse disciplines to promote further insights into the dynamic interplay between the virus and the host in areas of pathogenesis, mucosal biology, the roles of viral and host genes, and viral latency. Understanding these issues is critical for the design and development of an effective vaccine and the next generation of antiviral agents.
|
Registration Deadline: 21-Jan-2011
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1109
|
|
Protection from HIV: Targeted Intervention Strategies (X8)
20-Mar-2011 -
25-Mar-2011
Whistler
British Columbia
Canada
|
Biological efforts to prevent HIV infection center on four independent approaches: inducing adaptive immune responses through vaccination, augmenting innate responses, using peri-exposure prophylactic drug therapy, and developing microbicides and/or recombinant antiviral microbial products. While all four of these approaches have promise, they still require significant optimization and further clinical trials. Indeed, successful prevention of HIV infection will likely require a combination of these approaches. Such development efforts require a better understanding of viral and immunological events at the site of transmission. This Keystone Symposia meeting will have a focus on mucosal immunology as well as the interplay between the virus and innate and adaptive immune responses, particularly during the acute phase of the infection. Leading experts in the fields will discuss recent scientific advances in these varied approaches to preventing infection and present data from recent clinical trials testing their efficacy.
|
Registration Deadline: 21-Jan-2011
http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1110
|
|
|
|
